GLP-1 receptor agonists × glycemic control

TrialCurrent medical research and opinion2010

Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes.

Y Seino et al.PubMed ↗Publisher ↗

What the trial testedrandomised · 411 people · 2010

Randomised comparison

Probably lowered glycemic control

−0.72mmol/l−1.00 to −0.40

As reported

difference −0.72 mmol/l, 95% CI −1.00 to −0.40

Range includes no effect

No clear effect on glycemic control

−0.50percentage points−0.70 to +0.30

As reported

difference −0.5 %, 95% CI −0.70 to 0.30

Not counted

Probably lowered body weight & composition

−1.91kg−2.34 to −1.48

As reported

difference −1.91 kg, 95% CI −2.34 to −1.48

Three numbers in the abstract

the abstract, start to end

with glibenclamide (difference, -0.5%; 95% CI -0.70 to 0.30; p <

(8.3 mmol/l [+/-0.1]; difference, -0.72 mmol/l; 95% CI -1.0 to -0.4; p

64.8 kg with glibenclamide (difference, -1.91 kg; 95% CI -2.34 to -1.48; p <

← favours treatmentfavours comparator →
could be chance
Glycemic control
−0.5−0.70 to 0.30
Glycemic control
−0.72−1.00 to −0.40
Body weight & composition
−1.91−2.34 to −1.48
GLP-1 receptor agonistsSulfonylureas & glinidesGlycemic controlBody weight & composition

GLP-1 receptor agonists × glycemic controlhelps?replicated

unlikelylikely
0.910.91 without it

Sulfonylureas & glinides × glycemic controlhelps?settled

unlikelylikely
0.830.83 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 6

57 papers cite it

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
this paperpooled ittrialcites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 20199137